ATAD2 is an AAA+ ATPase family protein with a bromodomain that functions as an epigenetic regulator and transcriptional coactivator 1. As a histone chaperone, ATAD2 binds acetylated histones through its bromodomain to control chr8 dynamics and gene expression 2. Structurally, ATAD2 forms a hexameric spiral that regulates histone H3/H4 binding through allosteric mechanisms involving its N-terminal linker domain 3. ATAD2 participates in multiple cellular processes including transcriptional regulation, DNA replication, and nucleosome assembly/disassembly 1. In normal development, ATAD2 is a melanoma competence factor that complexes with SOX10 to enable neural crest developmental programs 4. In cancer pathology, ATAD2 is frequently overexpressed across multiple malignancies including gastrointestinal, reproductive, urological, lung, colorectal, and ovarian cancers 12. ATAD2 promotes tumorigenesis by cooperating with transcription factors—such as SOX9 in renal carcinoma—to establish super-enhancers that drive oncogenic gene expression programs 5. The protein is implicated in chemoresistance, cancer progression, and poor prognosis 1. Beyond cancer, ATAD2 modulates HIV-1 latency as a downstream host target, suggesting broader pathological relevance 6. Its dual AAA+ ATPase and bromodomain architecture makes ATAD2 an attractive but challenging therapeutic target, with emerging strategies including small-molecule inhibitors, RNA-based therapies, and monoclonal antibodies under investigation 27.